• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Approves mRNA-1283 COVID-19 Vaccine for Adults 65 and Older, Those With Underlying Conditions

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval, for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk for severe...

Q&A: High-fiber, plant-based diet may lower multiple myeloma risk

by Andrew (Drew) Rhoades; Francesca Castro, MS, RD, CDN | Jun 2, 2025 | Uncategorized

ORLANDO — A high-fiber, plant-based dietary intervention and nutritional counseling improved several risk factors for multiple myeloma, a study presented at the annual NUTRITION meeting showed.“Our study shows the power of nutrition in the preventive setting and...

Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in cUTIs Ends Early After Meeting Primary End Point

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles A clinical trial shows tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK) effectively treats complicated urinary tract infections (cUTIs), potentially transforming patient care and reducing hospital costs. Read...

New Jersey Society of Health-System Pharmacy Hosts 2nd Annual Pharmacy Leader and Pharmacy Technician Symposium

by MM360 Staff | Jun 2, 2025 | Myeloma News

Source: Pharmacy Times articles The NJSHP’s 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding. Read More

Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer

by MM360 Staff | Jun 2, 2025 | Uncategorized

Source: CureToday articles Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy. Read More
« Older Entries
Next Entries »

Recent Content

  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT